Peroxisome proliferator-activated receptor-γ and the endothelium: Implications in cardiovascular disease

Expert Review of Cardiovascular Therapy

Volumn 9, Issue 10, 2011, Pages 1279-1294

  Magri, Caroline Jane ^a,b   Gatt, Noel ^b,c   Xuereb, Robert G ^a,b   Fava, Stephen ^a,b  

^a MATER DEI HOSPITAL   (Malta)

^b UNIVERSITY OF MALTA MEDICAL SCHOOL   (Malta)

^c ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Endothelium; PPAR; Thiazoledinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTHELIN 1; GELATINASE B; HEME OXYGENASE 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; RAMIPRIL; REACTIVE OXYGEN METABOLITE; ROSIGLITAZONE; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ADRENERGIC SYSTEM; AGING; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR INFLAMMATION; CARDIOVASCULAR PARAMETERS; CAROTID ARTERY DISEASE; CELL MIGRATION; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; DIABETES MELLITUS; DIABETIC PATIENT; ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL PROGENITOR CELL; ENDOTHELIUM CELL; GLUCOSE TOLERANCE; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; IN-STENT RESTENOSIS; INSULIN DEPENDENT DIABETES MELLITUS; INTRAVASCULAR ULTRASOUND; METABOLIC REGULATION; MICROANGIOPATHY; NONHUMAN; OXIDATIVE STRESS; REVIEW; THROMBOSIS; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULAR AGING; VASCULAR ENDOTHELIUM; VASCULAR RHYTHM;

CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; HUMANS; PPAR GAMMA;

EID: 80053985403     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.11.140     Document Type: Review

References (204)

1. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347, 645-650 (1990).
2. Laudet V, Hanni C, Coll J, Catzeflis F, Stehelin D. Evolution of the nuclear receptor gene superfamily. EMBO J. 11, 1003-1013 (1992).
3. Miyata KS, McCaw SE, Marcus SL et al. The peroxisome proliferatoractivated receptor interacts with the retinoid X receptor in vivo. Gene 148, 327-330 (1994). (Pubitemid 24333694)
4. Berger J, Moller DE. The mechanisms of action of PPARs. Annu. Rev. Med. 53, 409-435 (2002). (Pubitemid 34177889)
5. Auwerx J. PPARγ, the ultimate thrifty gene. Diabetologia 42, 1033-1049 (1999).
6. Tontonoz P, Hu E, Graves RA et al. mPPAR g 2: tissue specific regulator of an adipocyte enhancer. Genes Dev. 8, 1224-1234 (1994).
7. Nedergaard J, Petrovic N, Lindgren EM et al. PPAR g in the control of brown adipocyte differentiation. Biochim. Biophys. Acta 1740, 293-304 (2005). (Pubitemid 40803456)
8. Braissant O, Foufelle F, Scotto C et al. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-a, -b, and -g in the adult rat. Endocrinology 137, 354-366 (1996). (Pubitemid 26005011)
9. Lai DY. Rodent carcinogenicity of peroxisome proliferators and issues on human relevance. J. Environ. Sci. Health C Environ. Carcinog. Ecotoxicol. Rev. 22(1), 37-55 (2004). (Pubitemid 38802823)
10. Peters JM, Cheung C, Gonzalez FJ. Peroxisome proliferator-activated receptor-α and liver cancer: where do we stand? J. Mol. Med. (Berl.) 83(10), 774-785 (2005). (Pubitemid 41407861)
11. Spiegelman BM. PPARγ: adipogenesis regulator and thiazoledinedione receptor. Diabetes 1998, 507-514 (1998). (Pubitemid 28160438)
12. Wilson TM, Brown PJ, Strenbach DD et al. The PPARs: from organ receptors to drug discovery. J. Med. Chem. 43, 527-550 (2000). (Pubitemid 30127149)
13. Marx N. PPARγ and vascular inflammation: adding another piece to the puzzle. Circ. Res. 91, 373-374 (2002). (Pubitemid 35034203)
14. Plutzky J. Peroxisome proliferator-activated receptors in endothelial cell biology. Curr. Opin. Lipidol. 12, 511-518 (2001). (Pubitemid 32980299)
15. Lowell BB. PPARγ: an essential regulator of adipogenesis and modulator of fat cell function. Cell 99, 239-242 (1999). (Pubitemid 29519902)
16. Zhang H, Zhang A, Kohan DE, Nelson RD, Gonzalez FJ, Yang T. Collecting duct-specific deletion of peroxisome proliferator-activated receptor g blocks thiazolidinedione-induced fluid retention. Proc. Natl Acad. Sci. USA 102, 9406-9411 (2005). (Pubitemid 40923576)
17. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev. 20, 649-688 (1999). (Pubitemid 30650602)
18. Schoonjans K, Auwerx J. Thiazoledinediones: an update. Lancet 355, 1008-1010 (2000).
19. Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, Lehmann JM. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor g and promotes adipocyte differentiation. Cell 83, 813-819 (1995). (Pubitemid 3006325)
20. Nagy L, Tontonoz P, Alvarez JG, Chen H, Evans RM. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ. Cell 93, 229-240 (1998). (Pubitemid 28180856)
21. Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans RM. PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93, 241-252 (1998). (Pubitemid 28180857)
22. Kawai M, Green CB, Lecka-Czernik B et al. A circadian-regulated gene, Nocturnin, promotes adipogenesis by stimulating PPAR-g nuclear translocation. Proc. Natl Acad. Sci. USA 107(23), 10508-10513 (2010).
23. Benson SC, Pershadsingh HA, Ho CI et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ- modulating activity. Hypertension 43, 993-1002 (2004). (Pubitemid 38579904)
24. Schupp M, Clemenz M, Gineste R et al. Molecular characterization of new selective peroxisome proliferator-activated receptor g modulators with angiotensin receptor blocking activity. Diabetes 54, 3442-3452 (2005). (Pubitemid 43334334)
25. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin Type 1 receptor blockers induce peroxisome proliferatoractivated receptor-γ activity. Circulation 109, 2054-2057 (2004). (Pubitemid 38620211)
26. Landmesser U, Hornig B, Drexler H. Endothelial function: a critical determinant in atherosclerosis? Circulation 109(21 Suppl. 1), II27-II33 (2004). (Pubitemid 38724153)
27. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation 115(10), 1285-1295 (2007). (Pubitemid 46594773)
28. Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 109(23 Suppl. 1), III27-III32 (2004). (Pubitemid 38786440)
29. Pober J, Cotran RS. Cytokines and endothelial cell biology. Physiol. Rev. 70, 427 (1990).
30. Faxon DP, Fuster V, Libby P et al. Atherosclerotic Vascular Disease Conference: Writing Group III: pathophysiology. Circulation 109(21), 2617-2625 (2004). (Pubitemid 38720566)
31. Kinlay S, Libby P, Ganz P. Endothelial function and coronary artery disease. Curr. Opin. Lipidol. 12(4), 383-389 (2001). (Pubitemid 32675498)
32. Sitia S, Tomasoni L, Atzeni F et al. From endothelial dysfunction to atherosclerosis. Autoimmun. Rev. 9(12), 830-834 (2010).
33. Kwaan HC, Samama MM. The significance of endothelial heterogeneity in thrombosis and hemostasis. Semin. Thromb. Hemost. 36(3), 286-300 (2010).
34. Gresele P, Momi S, Migliacci R. Endothelium, venous thromboembolism and ischaemic cardiovascular events. Thromb. Haemost. 103(1), 56-61 (2010).
35. Singh M, Mensah GA, Bakris G. Pathogenesis and clinical physiology of hypertension. Cardiol. Clin. 28(4), 545-559 (2010).
36. Dzau VJ, Braun-Dullaeus RC, Sedding DG. Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nat. Med. 8(11), 1249-1256 (2002). (Pubitemid 35373556)
37. Bishop-Bailey D, Hla T. Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-d12, 14-prostaglandin J2. J. Biol. Chem. 274, 17042-17048 (1999).
38. Kato K, Satoh H, Endo Y et al. Thiazolidinediones down-regulate plasminogen activator inhibitor Type 1 expression in human vascular endothelial cells: a possible role for PPARγ in endothelial function. Biochem. Biophys. Res. Commun. 258, 431-435 (1999). (Pubitemid 29287068)
39. Marx N, Bourcier T, Sukhova GK, Libby P, Plutzky J. PPARγ activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARγ as a potential mediator in vascular disease. Arterioscler. Thromb. Vasc. Biol. 19, 546-551 (1999). (Pubitemid 29135154)
40. Xin X, Yang S, Kowalski J, Gerritsen ME. Peroxisome proliferator- activated receptor γ ligands are potent inhibitors of angiogenesis in vitro and in vivo. J. Biol. Chem. 274, 9116-9121 (1999). (Pubitemid 29164719)
41. Law RE, Goetze S, Xi XP et al. Expression and function of PPARγ in rat and human vascular smooth muscle cells. Circulation 101, 1311-1318 (2000). (Pubitemid 30158620)
42. Marx N, Duez H, Fruchart JC et al. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ. Res. 94(9), 1168-1178 (2004). (Pubitemid 38656403)
43. Schiffrin EL. Peroxisome proliferator activated receptors and cardiovascular remodeling. Am. J. Physiol. Heart Circ. Physiol. 288(3), H1037-H1043 (2005). (Pubitemid 40270004)
44. Beyer AM, Baumbach GL, Halabi CM et al. Interference with PPARγ signaling causes cerebral vascular dysfunction, hypertrophy, and remodeling. Hypertension 51, 867-871 (2008). (Pubitemid 351654697)
45. Rius C, Abu-Taha M, Hermenegildo C et al. Trans- but not cis-resveratrol impairs angiotensin-II-mediated vascular inflammation through inhibition of NF-kB activation and peroxisome proliferator-activated receptor-γ upregulation. J. Immunol. 185(6), 3718-3727 (2010).
46. Bruemmer D, Blaschke F, Law RE. New targets for PPARγ in the vessel wall: implications for restenosis. Int. J. Obes. (Lond.) 29 (Suppl. 1), S26-S30 (2005). (Pubitemid 40343168)
47. Diep QN, El Mabrouk M, Cohn JS et al. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-γ. Circulation 105, 2296-2302 (2002). (Pubitemid 34535341)
48. Jackson SM, Parhami F, Xi XP et al. Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. Arterioscler. Thromb. Vasc. Biol. 19, 2094-2104 (1999). (Pubitemid 29422240)
49. Nawa T, Nawa MT, Cai Y et al. Repression of TNF-α induced E-selectin expression by PPAR activators: involvement of transcriptional repressor LRF-1/ATF3. Biochem. Biophys. Res. Commun. 275, 406-411 (2000).
50. Pasceri V, Wu HD, Willerson JT, Yeh ET. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-γ activators. Circulation 101, 235-238 (2000). (Pubitemid 30054148)
51. Wang N, Verna L, Chen NG et al. Constitutive activation of peroxisome proliferator-activated receptor-γ suppresses proinflammatory adhesion molecules in human vascular endothelial cells. J. Biol. Chem. 277, 34176-34181 (2002).
52. Collins T, Read MA, Neish AS, Whitley MZ, Thanos D, Maniatis T. Transcriptional regulation of endothelial cell adhesion molecules: NF-kB and cytokine inducible enhancers. FASEB J. 9, 899-909 (1995).
53. Takata Y, Kitami Y, Yang ZH et al. Vascular inflammation is negatively autoregulated by interaction between CCAAT/enhancer-binding protein-δ and peroxisome proliferator-activated receptor-γ. Circ. Res. 91, 427-433 (2002). (Pubitemid 35034211)
54. Delerive P, Martin-Nizard F, Chinetti G et al. Peroxisome proliferator-activated receptor activators inhibit thrombininduced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ. Res. 85, 394-402 (1999). (Pubitemid 29409616)
55. Zhou YC, Waxman DJ. Cross-talk between janus kinase signal transducer and activator of transcription (JAK-STAT) and peroxisome proliferator-activated receptor-α (PPARα) signaling pathways: growth hormone inhibition of PPARα transcriptional activity mediated by stat5b. J. Biol. Chem. 274, 2672-2681 (1999). (Pubitemid 29075346)
56. Verrier E, Wang L, Wadham C et al. PPARγ agonists ameliorate endothelial cell activation via inhibition of diacylglycerolprotein kinase C signaling pathway: role of diacylglycerol kinase. Circ. Res. 94, 1515-1522 (2004). (Pubitemid 38780325)
57. Kronke G, Kadl A, Ikonomu E et al. Expression of heme oxygenase-1 in human vascular cells is regulated by peroxisome proliferator-activated receptors. Arterioscler. Thromb. Vasc. Biol. 27, 1276-1282 (2007). (Pubitemid 46809415)
58. Hwang J, Kleinhenz DJ, Lassegue B, Griendling KK, Dikalov S, Hart CM. Peroxisome proliferator-activated receptor-γ ligands regulate endothelial membrane superoxide production. Am. J. Physiol. Cell Physiol. 288, C899-C905 (2005). (Pubitemid 40395068)
59. Mehta JL, Hu B, Chen J, Li D. Pioglitazone inhibits LOX-1 expression in human coronary artery endothelial cells by reducing intracellular superoxide radical generation. Arterioscler. Thromb. Vasc. Biol. 23, 2203-2208 (2003). (Pubitemid 37532321)
60. Jung Y, Song S, Choi C. Peroxisome proliferator activated receptor γ agonists suppress TNF-α-induced ICAM-1 expression by endothelial cells in a manner potentially dependent on inhibition of reactive oxygen species. Immunol. Lett. 117(1), 63-69 (2008).
61. Kwak BR, Myit S, Mulhaupt F et al. PPARγ but not PPARα ligands are potent repressors of major histocompatibility complex class II induction in atheromaassociated cells. Circ. Res. 90, 356-362 (2002). (Pubitemid 34633938)
62. Rozani B, Chakravarthy MV, Semenkovich CF. Insulin resistance and atherosclerosis. Endocrinol. Metab. Clin. North Am. 37, 603-621 (2008).
63. Fukunaga Y, Itoh H, Doi K et al. Thiazolidinediones, peroxisome proliferator-activated receptor γ agonists, regulate endothelial cell growth and secretion of vasoactive peptides. Atherosclerosis 158, 113-119 (2001). (Pubitemid 32735474)
64. Iglarz M, Touyz RM, Amiri F, Lavoie MF, Diep QN, Schiffrin EL. Effect of peroxisome proliferator-activated receptor-α and -γ activators on vascular remodeling in endothelin-dependent hypertension. Arterioscler. Thromb. Vasc. Biol. 23, 45-51 (2003). (Pubitemid 36091624)
65. Martin-Nizard F, Furman C, Delerive P et al. Peroxisome proliferator-activated receptor activators inhibit oxidized low-density lipoprotein-induced endothelin-1 secretion in endothelial cells. J. Cardiovasc. Pharmacol. 40, 822-831 (2002). (Pubitemid 35365080)
66. Satoh H, Tsukamoto K, Hashimoto Y et al. Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells: a new possible role of PPARγ on vascular endothelial function. Biochem. Biophys. Res. Commun. 254, 757-763 (1999). (Pubitemid 29290541)
67. Salomone OA, Elliott PM, Calvino R et al. Plasma immunoreactive endothelin concentration correlates with severity of coronary artery disease in patients with stable angina pectoris and normal ventricular function. J. Am. Coll. Cardiol. 28, 14-19 (1996). (Pubitemid 26266617)
68. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327, 524-526 (1987). (Pubitemid 17085822)
69. Ríos-Vázquez R, Marzoa-Rivas R, Gil-Ortega I, Kaski JC. Peroxisome proliferator-activated receptor-γ agonists for management and prevention of vascular disease in patients with and without diabetes mellitus. Am. J. Cardiovasc. Drugs 6(4), 231-242 (2006). (Pubitemid 44285132)
70. Calnek DS, Mazzella L, Roser S, Roman J, Hart CM. Peroxisome proliferatoractivated receptor g ligands increase release of nitric oxide from endothelial cells. Arterioscler. Thromb. Vasc. Biol. 23, 52-57 (2003). (Pubitemid 36091625)
71. Cho DH, Choi YJ, Jo SA, Jo I. Nitric oxide production and regulation of endothelial nitric-oxide synthase phosphorylation by prolonged treatment with troglitazone: evidence for involvement of peroxisome proliferator activated receptor (PPAR) g-dependent and PPARγ- independent signaling pathways. J. Biol. Chem. 279, 2499-2506 (2004). (Pubitemid 38114233)
72. Polikandriotis JA, Mazzella LJ, Rupnow HL, Hart CM. Peroxisome proliferatoractivated receptor g ligands stimulate endothelial nitric oxide production through distinct peroxisome proliferator-activated receptor g-dependent mechanisms. Arterioscler. Thromb. Vasc. Biol. 25, 1810-1816 (2005). (Pubitemid 41243447)
73. Bagi Z, Koller A, Kaley G et al. PPARγ activation, by reducing oxidative stress, increases NO bioavailability in coronary arterioles of mice with Type 2 diabetes. Am. J. Physiol. Heart Circ. Physiol. 286, H742-H748 (2004). (Pubitemid 38140357)
74. Goya K, Sumitani S, Otsuki M et al. The thiazolidinedione drug troglitazone up-regulates nitric oxide synthase expression in vascular endothelial cells. J. Diabetes Complicat. 20, 336-342 (2006). (Pubitemid 44292533)
75. Ptasinska A, Wang S, Zhang J, Wesley RA, Danner RL. Nitric oxide activation of peroxisome proliferator-activated receptor g through a p38 MAPK signaling pathway. FASEB J. 21, 950-961 (2007). (Pubitemid 46348267)
76. Tao L, Liu HR, Gao E, Teng ZP et al. Antioxidative, antinitrative, and vasculoprotective effects of a peroxisome proliferator-activated receptorg agonist in hypercholesterolemia. Circulation 108, 2805-2811 (2003). (Pubitemid 37498984)
77. Aitman TJ, Glazier AM, Wallace CA et al. Identification of Cd36 (Fat) as an insulin-resistance gene causing defective fatty acid and glucose metabolism in hypertensive rats. Nat. Genet. 21, 76-83 (1999). (Pubitemid 29036288)
78. Barroso I, Gurnell M, Crowley VEF et al. Dominant negative mutations in human PPAR-g associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 402, 880-883 (1999).
79. Diep QN and Schiffrin EL. Increased expression of peroxisome proliferatoractivated receptor-α and -g in blood vessels of spontaneously hypertensive rats. Hypertension 38, 249-254 (2001). (Pubitemid 34224753)
80. Nicol CJ, Adachi M, Akiyama TE, Gonzalez FJ. PPARγ in endothelial cells influences high fat diet-induced hypertension. Am. J. Hypertens. 18, 549-556 (2005).
81. Lu Z, Dong B, Mo X et al. Pro12Ala polymorphism in PPARγ2 associated with essential hypertension in Chinese nonagenarians/centenarians. Exp. Gerontol. 43(12), 1108-1113 (2008).
82. Kuliczkowska J, Filus A, Trzmiel A et al. PPAR-g2 Pro12Ala polymorphism in the population of obese and non-obese men of the city of Wroclaw. Endokrynol Pol. 59(4), 312-315 (2008).
83. Kim K, Lee S, Valentine RJ. Association of pro12Ala polymorphism in the peroxisome proliferative-activated receptor g2 gene with obesity and hypertension in Korean women. J. Nutr. Sci. Vitaminol. (Tokyo) 53(3), 239-246 (2007). (Pubitemid 47217221)
84. Bakris FL, Dole JF, Porter LE et al. Rosiglitazone improves blood pressure in patients with Type 2 diabetes mellitus. Diabetes 49, A96 (2000).
85. Qayyum R, Adomaityte J. A meta-analysis of the effect of thiazolidinediones on blood pressure. J. Clin. Hypertens. (Greenwich) 8(1), 19-28 (2006).
86. Ogihara T, Rakugi H, Ikegami H et al. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am. J. Hypertens. 8, 316-320 (1995).
87. Walker AB, Naderali EK, Chattington PD, Buckingham RE, Williams G. Differential vasoactive effects of the insulin sensitizers rosiglitazone (BRL 49653) and troglitazone on human small arteries in vitro. Diabetes 47, 810-814 (1998). (Pubitemid 28201812)
88. Hamblin M, Chang L, Fan Y, Zhang J, Chen YE. PPARs and the cardiovascular system. Antioxid. Redox Signal. 11(6), 1415-1452 (2009).
89. Goetze S, Bungenstock A, Czupalla C et al. Leptin induces endothelial cell migration through Akt, which is inhibited by PPARγ-ligands. Hypertension 40, 748-754 (2002). (Pubitemid 35278614)
90. Hannan KM, Dilley RJ, de Dios ST, Little PJ. Troglitazone stimulates repair of the endothelium and inhibits neointimal formation in denuded rat aorta. Arterioscler. Thromb. Vasc. Biol. 23, 762-768 (2003). (Pubitemid 36566164)
91. Lee KS, Park JH, Lee S, Lim HJ, Jang Y, Park HY. Troglitazone inhibits endothelial cell proliferation through suppression of casein kinase 2 activity. Biochem. Biophys. Res. Commun. 346, 83-88 (2006). (Pubitemid 43865970)
92. Levonen AL, Dickinson DA, Moellering DR, Mulcahy RT, Forman HJ, Darley- Usmar VM. Biphasic effects of 15-deoxyd( 12,14)-prostaglandin J(2) on glutathione induction and apoptosis in human endothelial cells. Arterioscler. Thromb. Vasc. Biol. 21, 1846-1851 (2001). (Pubitemid 34219791)
93. Zhang J, Fu M, Zhao L, Chen YE. 15-Deoxyprostaglandin J(2) inhibits PDGF-A and -B chain expression in human vascular endothelial cells independent of PPAR g. Biochem. Biophys. Res. Commun. 298, 128-132 (2002). (Pubitemid 35205397)
94. Inoue I, Hayashi K, Yagasaki F et al. Apoptosis of endothelial cells may be mediated by genes of peroxisome proliferator-activated receptor g 1 (PPARγ 1) and PPARα genes. J. Atheroscler. Thromb. 10, 99-108 (2003).
95. Ameshima S, Golpon H, Cool CD et al. Peroxisome proliferator-activated receptor g (PPARγ) expression is decreased in pulmonary hypertension and affects endothelial cell growth. Circ. Res. 92, 1162-1169 (2003). (Pubitemid 36665863)
96. Kim KY, Cheon HG. Antiangiogenic effect of rosiglitazone is mediated via peroxisome proliferator-activated receptor g-activated maxi-K channel opening in human umbilical vein endothelial cells. J. Biol. Chem. 281, 13503-13512 (2006).
97. Scoditti E, Massaro M, Carluccio MA, Distante A, Storelli C, De Caterina R. PPARγ agonists inhibit angiogenesis by suppressing PKCa- and CREB-mediated COX-2 expression in the human endothelium. Cardiovasc. Res. 86(2), 302-310 (2010).
98. Xin X, Yang S, Kowalski J, Gerritsen ME. Peroxisome proliferator- activated receptor ligands are potent inhibitors of angiogenesis in vitro and in vivo. J. Biol. Chem. 274(13), 9116-9121 (1999). (Pubitemid 29164719)
99. Chintalgattu V, Harris GS, Akula SM, Katwa LC. PPAR-g agonists induce the expression of VEGF and its receptors in cultured cardiac myofibroblasts. Cardiovasc. Res. 74(1), 140-150 (2007). (Pubitemid 46366953)
100. Panigrahy D, Singer S, Shen LQ et al. PPARγ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J. Clin. Invest. 110, 923-932 (2002).
101. Shen LQ, Child A, Weber GM, Folkman J, Aiello LP. Rosiglitazone and delayed onset of proliferative diabetic retinopathy. Arch. Ophthalmol. 126(6), 793-799 (2008). (Pubitemid 351831328)
102. Biscetti F, Gaetani E, Flex A et al. Selective activation of peroxisome proliferatoractivated receptor (PPAR)a and PPAR g induces neoangiogenesis through a vascular endothelial growth factor-dependent mechanism. Diabetes 57(5), 1394-1404 (2008).
103. Caplan BA, Schwartz CJ. Increased endothelial cell turnover in areas of in vivo Evans Blue uptake in the pig aorta. Atherosclerosis 17(3), 401-417 (1973).
104. Asahara T, Murohara T, Sullivan A et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 275(5302), 964-967 (1997). (Pubitemid 27087709)
105. Sorrentino SA, Bahlmann FH, Besler C et al. Oxidant stress impairs in vivo reendothelialization capacity of endothelial progenitor cells from patients with Type 2 diabetes mellitus: restoration by the peroxisome proliferator-activated receptor-γ agonist rosiglitazone. Circulation 116(2), 163-173 (2007). (Pubitemid 47057522)
106. Walter DH, Rittig K, Bahlmann FH et al. Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation 105(25), 3017-3024 (2002). (Pubitemid 34693836)
107. Werner N, Priller J, Laufs U et al. Bone marrow-derived progenitor cells modulate vascular reendothelialization and neointimal formation: effect of 3-hydroxy- 3-methylglutaryl coenzyme a reductase inhibition. Arterioscler. Thromb. Vasc. Biol. 22(10), 1567-1572 (2002).
108. Kawamoto A, Gwon HC, Iwaguro H et al. Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. Circulation 103(5), 634-637 (2001). (Pubitemid 32144189)
109. Wassmann S, Werner N, Czech T et al. Improvement of endothelial function by systemic transfusion of vascular progenitor cells. Circ. Res. 99(8), E74-E83 (2006). (Pubitemid 44556373)
110. Foteinos G, Hu Y, Xiao Q et al. Rapid endothelial turnover in atherosclerosisprone areas coincides with stem cell repair in apolipoprotein E-deficient mice. Circulation 117(14), 1856-1863 (2008). (Pubitemid 351507474)
111. Abou-Saleh H, Yacoub D, Theoret JF et al. Endothelial progenitor cells bind and inhibit platelet function and thrombus formation. Circulation 120, 2230-2239 (2009).
112. Hill JM, Zalos G, Halcox JP et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N. Engl. J. Med. 348(7), 593-600 (2003). (Pubitemid 36204953)
113. Vasa M, Fichtlscherer S, Aicher A et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ. Res. 89(1), e1-e7 (2001).
114. Thum T, Tsikas D, Stein S et al. Suppression of endothelial progenitor cells in human coronary artery disease by the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine. J. Am. Coll. Cardiol. 46(9), 1693-1701 (2005). (Pubitemid 41531624)
115. Valgimigli M, Rigolin GM, Fucili A et al. CD34+ and endothelial progenitor cells in patients with various degrees of congestive heart failure. Circulation 110(10), 1209-1212 (2004). (Pubitemid 39202334)
116. Fadini GP, Miorin M, Facco M et al. Circulating endothelial progenitor cells are reduced in peripheral vascular complications of Type 2 diabetes mellitus. J. Am. Coll. Cardiol. 45(9), 1449-1457 (2005). (Pubitemid 40615617)
117. Ghani U, Shuaib A, Salam A et al. Endothelial progenitor cells during cerebrovascular disease. Stroke 36(1), 151-153 (2005). (Pubitemid 40054193)
118. Prokopi M, Pula G, Mayr U et al. Proteomic analysis reveals presence of platelet microparticles in endothelial progenitor cell cultures. Blood 114, 723-732 (2009).
119. Wang CH, Ciliberti N, Li SH et al. Rosiglitazone facilitates angiogenic progenitor cell differentiation toward endothelial lineage: a new paradigm in glitazone pleiotropy. Circulation 109(11), 1392-1400 (2004). (Pubitemid 38387826)
120. Pistrosch F, Herbrig K, Oelschlaegel U et al. PPAR-g-agonist rosiglitazone increases number and migratory activity of cultured endothelial progenitor cells. Atherosclerosis 183(1), 163-167 (2005). (Pubitemid 41416835)
121. Wang CH, Ting MK, Verma S et al. Pioglitazone increases the numbers and improves the functional capacity of endothelial progenitor cells in patients with diabetes mellitus. Am. Heart J. 152(6), e1051-e1058 (2006).
122. Gensch C, Clever YP, Werner C et al. The PPAR-g agonist pioglitazone increases neoangiogenesis and prevents apoptosis of endothelial progenitor cells. Atherosclerosis 192(1), 67-74 (2007). (Pubitemid 46628806)
123. Werner C, Kamani CH, Gensch C, Bohm M, Laufs U. The peroxisome proliferatoractivated receptor-γ agonist pioglitazone increases number and function of endothelial progenitor cells in patients with coronary artery disease and normal glucose tolerance. Diabetes 56, 2609-2615 (2007). (Pubitemid 47523269)
124. Pistrosch F, Passauer J, Fischer S, Fuecker K, Hanefeld M, Gross P. In Type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care 27, 484-490 (2004). (Pubitemid 38174076)
125. Verma S, Kuliszewski MA, Li SH et al. C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation 109, 2058-2067 (2004). (Pubitemid 38620212)
126. Hur J, Yoon CH, Kim HS et al. Characterization of two types of endothelial progenitor cells and their different contributions to neovasculogenesis. Arterioscler. Thromb. Vasc. Biol. 24, 288-293 (2004). (Pubitemid 38197580)
127. Yoon CH, Hur J, Park KW et al. Synergistic neovascularization by mixed transplantation of early endothelial progenitor cells and late outgrowth endothelial cells: the role of angiogenic cytokines and matrix metalloproteinases. Circulation 112, 1618-1627 (2005). (Pubitemid 41324524)
128. Cleaver O, Melton DA. Endothelial signaling during development. Nat. Med. 9, 661-668 (2003). (Pubitemid 36749214)
129. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J. Clin. Invest. 97, 2601-2610 (1996).
130. Meigs JB, Hu FB, Rifai N, Manson JE. Biomarkers of endothelial dysfunction and risk of Type 2 diabetes mellitus. JAMA 29, 1978-1986 (2004). (Pubitemid 38544279)
131. Kanda T, Brown JD, Orasanu G et al. PPARγ in the endothelium regulates metabolic responses to high-fat diet in mice. J. Clin. Invest. 119(1), 110-124 (2009).
132. Yki-Järvinen H. Thiazolidinediones and the liver in humans. Curr. Opin. Lipidol. 20(6), 477-483 (2009).
133. Lutchman G, Promrat K, Kleiner DE et al. Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histological improvement. Clin. Gastroenterol. Hepatol. 4(8), 1048-1052 (2006). (Pubitemid 44118842)
134. Eddy AA. Plasminogen activator inhibitor-1 and the kidney. Am. J. Physiol. Renal Physiol. 283, F209-F220 (2002). (Pubitemid 34778983)
135. Thogersen AM, Jansson JH, Boman K et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 98, 2241-2247 (1998). (Pubitemid 28533841)
136. Kohler HP, Grant PJ. Plasminogenactivator inhibitor Type 1 and coronary artery disease. N. Engl. J. Med. 342, 1792-1801 (2000). (Pubitemid 30390240)
137. Zunker P, Schick A, Padro T, Kienast J, Phillips A, Ringelstein EB. Tissue plasminogen activator and plasminogen activator inhibitor in patients with acute ischemic stroke: relation to stroke etiology. Neurol. Res. 21, 727-732 (1999).
138. Collet JP, Montalescot G, Vicaut E et al. Acute release of plasminogen activator inhibitor-1 in ST-segment elevation myocardial infarction predicts mortality. Circulation 108, 391-339 (2003).
139. Rosito GA, D'Agostino RB, Massaro J et al. Association between obesity and a prothrombotic state: the Framingham Offspring Study. Thromb. Haemost. 91, 683-689 (2004). (Pubitemid 38477447)
140. Eliasson M, Evrin PE, Lundblad D. Fibrinogen and fibrinolytic variables in relation to anthropometry, lipids and blood pressure. The Northern Sweden MONICA Study. J. Clin. Epidemiol. 47, 513-524 (1994). (Pubitemid 24171216)
141. Peraldi MN, Rondeau E, Medcalf RL et al. Cell-specific regulation of plasminogen activator inhibitor 1 and tissue type plasminogen activator release by human kidney mesangial cells. Biochim. Biophys. Acta 1134, 189-196 (1992).
142. Lucore CL, Fujii S, Wun TC, Sobel BE, Billadello JJ. Regulation of the expression of Type 1 plasminogen activator inhibitor in Hep G2 cells by epidermal growth factor. J. Biol. Chem. 263, 15845-15848 (1988). (Pubitemid 18261990)
143. Alessi MC, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes 46, 860-867 (1997). (Pubitemid 27188265)
144. Hong HK, Cho YM, Park KH, Lee CT, Lee HK, Park KS. Peroxisome proliferatoractivated receptor g mediated inhibition of plasminogen activator inhibitor Type 1 production and proliferation of human umbilical vein endothelial cells. Diabetes Res. Clin. Pract. 62, 1-8 (2003). (Pubitemid 37315889)
145. Nordt TK, Sawa H, Fujii S, Bode C, Sobel BE. Augmentation of arterial endothelial cell expression of the plasminogen activator inhibitor type-1 (PAI-1) gene by proinsulin and insulin in vivo. J. Mol. Cell Cardiol. 30, 1535-1543 (1998). (Pubitemid 28418644)
146. Hamaguchi E, Takamura T, Shimizu A, Nagai Y. Tumor necrosis factor-α and troglitazone regulate plasminogen activator inhibitor Type 1 production through extracellular signal-regulated kinase- and nuclear factor κB-dependent pathways in cultured human umbilical vein endothelial cells. J. Pharmacol. Exp. Ther. 307, 987-994 (2003). (Pubitemid 37494216)
147. Wang N, Yang G, Jia Z et al. Vascular PPAR γ controls circadian variation in blood pressure and heart rate through Bmal1. Cell Metab. 8(6), 482-491 (2008).
148. Najjar SS, Scuteri A, Lakatta EG. Arterial aging: is it an immutable cardiovascular risk factor? Hypertension 46(3), 454-462 (2005). (Pubitemid 41376818)
149. Nagai Y, Metter EJ, Earley CJ et al. Increased carotid artery intimal-medial thickness in asymptomatic older subjects with exercise-induced myocardial ischemia. Circulation 98, 1504-1509 (1998). (Pubitemid 28481666)
150. Virmani R, Avolio AP, Mergner WJ et al. Effect of aging on aortic morphology in populations with high and low prevalence of hypertension and atherosclerosis. Comparison between occidental and Chinese communities. Am. J. Pathol. 139, 1119-1129 (1991).
151. Lakatta EG, Wang M, Najjar SS. Arterial aging and subclinical arterial disease are fundamentally intertwined at macroscopic and molecular levels. Med. Clin. North Am. 93(3), 583-604 (2009).
152. Chang E, Harley CB. Telomere length and replicative aging in human vascular tissues. Proc. Natl Acad. Sci. USA 92, 11190-11194 (1995).
153. Minamino T, Miyauchi H, Yoshida T, Ishida Y, Yoshida H, Komuro I. Endothelial cell senescence in human atherosclerosis. Role of telomere in endothelial dysfunction. Circulation 105, 1541-1544 (2002). (Pubitemid 34297628)
154. Ogami M, Ikura Y, Ohsawa M et al. Telomere shortening in human coronary artery diseases. Arterioscler. Thromb. Vasc. Biol. 24(3), 546-550 (2004). (Pubitemid 38326151)
155. Werner C, Gensch C, Pöss J, Haendeler J, Böhm M, Laufs U. Pioglitazone activates aortic telomerase and prevents stressinduced endothelial apoptosis. Atherosclerosis 216(1), 23-34 (2011).
156. Imanishi T, Kobayashi K, Kuroi A, Ikejima H, Akasaka T. Pioglitazone inhibits angiotensin II-induced senescence of endothelial progenitor cell. Hypertens. Res. 31(4), 757-765 (2008). (Pubitemid 351772867)
157. Makino N, Maeda T, Oyama J, Higuchi Y, Mimori K. Improving insulin sensitivity via activation of PPAR-g increases telomerase activity in the heart of OLETF rats. Am. J. Physiol. Heart Circ. Physiol. 297(6), H2188-H2195 (2009).
158. Wang M, Zhang J, Jiang LQ et al. Proinflammatory profile within the grossly normal aged human aortic wall. Hypertension. 50, 219-227 (2007). (Pubitemid 46986044)
159. Mahmud A, Feely J. Arterial stiffness is related to systemic inflammation in essential hypertension. Hypertension 46, 1118-1122 (2005). (Pubitemid 41533013)
160. Sung B, Park S, Yu BP, Chung HY. Modulation of PPAR in aging, inflammation, and calorie restriction. J. Gerontol. A Biol. Sci. Med. Sci. 59, 997-1006 (2004). (Pubitemid 39441788)
161. Haffner SM, Greenberg AS, Weston WM et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with Type 2 diabetes mellitus. Circulation 106, 679-684 (2002). (Pubitemid 34851926)
162. Pfutzner A, Marx N, Lubben G et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycaemic control results from the pioneer study. J. Am. Coll. Cardiol. 45, 1925-1931 (2005). (Pubitemid 40814110)
163. Mohanty P, Aljada A, Ghanim H et al. Evidence for a potent anti-inflammatory effect of rosiglitazone. J. Clin. Endocrinol. Metab. 89, 2728-2735 (2004).
164. Campia U, Matuskey LA, Panza JA. Peroxisome proliferator-activated receptor-γ activation with pioglitazone improves endothelium-dependent dilation in nondiabetic patients with major cardiovascular risk factors. Circulation 113(6), 867-875 (2006).
165. Varo N, Vicent D, Libby P et al. Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones. Circulation 107, 2664-2669 (2003). (Pubitemid 36667238)
166. Marx N, Imhof A, Froehlich J et al. Effect of rosiglitazone treatment on soluble CD40L in patients with Type 2 diabetes and coronary artery disease. Circulation 107, 1954-1957 (2003). (Pubitemid 36506065)
167. Sidhu JS, Cowan D, Kaski JC. The effects of rosiglitazone, a peroxisome proliferatoractivated receptor-γ agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in nondiabetic coronary artery disease patients. J. Am. Coll. Cardiol. 42, 1757-1763 (2003). (Pubitemid 37433654)
168. Wang TD, Chen WJ, Lin JW, Chen MF, Lee YT. Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome. Am. J. Cardiol. 93, 362-365 (2004).
169. Martens FM, Visserens FL, de Koning EJ et al. Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with Type 2 diabetes. J. Cardiovasc. Pharmacol. 46, 773-778 (2005). (Pubitemid 44378249)
170. Patel SR, Mailloux LM, Coppola JT, Mindrescu C, Staniloae CS. Pioglitazone increases adiponectin levels in nondiabetic patients with coronary artery disease. Coron. Artery Dis. 19(5), 349-353 (2008).
171. Staniloae C, Mandadi V, Kurian D et al. Pioglitazone improves endothelial function in non-diabetic patients with coronary artery disease. Cardiology 108(3), 164-169 (2007). (Pubitemid 47525213)
172. Caballero AE, Saouaf R, Lim SC et al. The effects of troglitazone, an insulinsensitizing agent, on the endothelial function in early and late Type 2 diabetes: a placebo-controlled randomized clinical trial. Metabolism 52(2), 173-180 (2003). (Pubitemid 36388839)
173. Yu J, Zhang Z, Li X et al. Peroxisome proliferator-activated receptor-γ agonist improves coronary artery endothelial function in diabetic patients with coronary artery disease. J. Int. Med. Res. 38, 86-94 (2010).
174. Melmoun P, Tribouilloy C. Non-invasive assessment of coronary flow and coronary flow reserve by transthoracic Doppler echocardiography: a magic tool for the real world. Eur. J. Echocardiogr. 9, 449-457 (2008). (Pubitemid 351882110)
175. Minamikawa J, Tanaka S, Yamauchi M et al. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in Type 2 diabetes. J. Clin. Endocrinol. Metabol. 83, 1818-1820 (1998). (Pubitemid 28501066)
176. Koshiyama H, Shimono D, Kuwamura N et al. Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in Type 2 diabetes. J. Clin. Endocrinol. Metab. 86, 3452-3456 (2001). (Pubitemid 32673521)
177. Mizuhige K, Noma T, Yao L et al. Effects of troglitazone on collagen accumulation and distensibility of aortic wall in prestage of non-insulin dependent diabetes mellitus of Otsuka Long-Evans Tokushima Fatty rats. J. Cardiovasc. Pharmacol. 35(1), 150-155 (2000). (Pubitemid 30032907)
178. Lonn EM, Gerstein HC, Sheridan P et al.; DREAM (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication) and STARR Investigators. Effect of ramipril and of rosiglitazone on carotid intima-media thickness in people with impaired glucose tolerance or impaired fasting glucose: STARR (Study of Atherosclerosis with Ramipril and Rosiglitazone). J. Am. Coll. Cardiol. 53(22), 2028-2035 (2009).
179. Sidhu JS, Kaposzta Z, Markus HS et al. Effect of rosiglitazone on common carotid intima-media thickness in coronary artery disease patients without diabetes mellitus. Arterioscler. Thromb. Vasc. Biol. 24, 930-934 (2004). (Pubitemid 38620874)
180. Baldassarre D, Veglia F, Gobbi C et al. Intima-media thickness after pravastatin stabilizes also in patients with moderate to no reduction in LDL-cholesterol levels: the carotid atherosclerosis Italian ultrasound study. Atherosclerosis 151(2), 575-583 (2000). (Pubitemid 30618777)
181. Wiklund O, Hulthe J, Wikstrand J et al. Effect of controlled release/extended release metoprolol on carotid intima-media thickness in patients with hypercholesterolaemia: a 3-year randomized study. Stroke 33, 572-577 (2002). (Pubitemid 34123409)
182. Smyth SS, Jennings JL. PPARγ agonists: a new strategy for antithrombotic therapy. J. Thromb. Haemost. 3, 2147-2148 (2005). (Pubitemid 41727188)
183. Takagi T, Akasada T, Yamamuro A et al. Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus. J. Am. Coll. Cardiol. 36, 1529-1535 (2000).
184. Takagi T, Yamamuro A, Tamita K et al. Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with Type 2 diabetes mellitus: an intravascular ultrasound scanning study. Am. Heart J. 146, E5 (2003).
185. Choi D, Kim SK, Choi SH et al. Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with Type 2 diabetes. Diabetes Care 27, 2654-2660 (2004). (Pubitemid 39441466)
186. Satoh N, Ogawa Y, Usui T et al. Antiatherogenic effect of pioglitazone in Type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 26, 2493-2499 (2003). (Pubitemid 37055444)
187. Ryan KE, McCance DR, Powell L, McMahon R, Trimble ER. Fenofibrate and pioglitazone improve endothelial function and reduce arterial stiffness in obese glucose tolerant men. Atherosclerosis 194(2), e123-e130 (2007). (Pubitemid 47513101)
188. Ridker PM, Cook NR, Cheng S et al. Alanine for proline substitution in the peroxisome proliferator-activated receptor g-2 (PPARG2) gene and the risk of incident myocardial infarction. Arterioscler. Thromb. Vasc. Biol. 23, 859-863 (2003). (Pubitemid 36566178)
189. Pischon T, Pai JK, Manson JE et al. Peroxisome proliferator-activated receptor-2 p12a polymorphism and risk of coronary heart disease in us men and women. Atherosclerosis and lipoproteins. Arterioscler. Thromb. Vasc. Biol. 25(8), 1654-1658 (2005). (Pubitemid 41098936)
190. Li L, Cheng LX, Nsenga R, He MA, Wu TC. Association between Pro12Ala polymorphism of peroxisome proliferatoractivated receptor-γ 2 and myocardial infarction in the Chinese Han population. Clin. Cardiol. 29(7), 300-304 (2006). (Pubitemid 44050258)
191. Zafarmand MH, van der Schouw YT, Grobbee DE, de Leeuw PW, Bots ML. Peroxisome proliferator-activated receptor g-2 P12A polymorphism and risk of acute myocardial infarction, coronary heart disease and ischemic stroke: a case-cohort study and meta-analyses. Vasc. Health Risk Manag. 4(2), 427-436 (2008). (Pubitemid 351711971)
192. Regieli JJ, Jukema JW, Doevendans PA et al. PPAR g variant influences angiographic outcome and 10-year cardiovascular risk in male symptomatic coronary artery disease patients. Diabetes Care 32(5), 839-844 (2009).
193. Liu Y, Yuan Z, Liu Y et al. PPARγ gene C161T substitution is associated with reduced risk of coronary artery disease and decreased proinflammatory cytokine expression. Am. Heart J. 154(4), 718-724 (2007). (Pubitemid 47429582)
194. Gerstein HC, Yusuf S, Bosch J; Diabetes Reduction Assessment With Ramipril and Rosiglitazone Medication Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368(9541), 1096-1105 (2006).
195. Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med. 355(23), 2427-2443 (2006). (Pubitemid 44903747)
196. Home PD, Pocock SJ, Beck-Nielsen H et al.; RECORD Study Group. Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis. N. Engl. J. Med. 357(1), 28-38 (2007). (Pubitemid 47026732)
197. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 298(10), 1189-1195 (2007). (Pubitemid 47403105)
198. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 356(24), 2457-2471 (2007). (Pubitemid 46919772)
199. Mannucci E, Monami M, Di Bari M et al. Cardiac safety profile of rosiglitazone: a comprehensive meta-analysis of randomized clinical trials. Int. J. Cardiol. 143(2), 135-140 (2010).
200. Dahabreh IJ, Economopoulos K. Metaanalysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone. Clin. Trials 5(2), 116-120 (2008). (Pubitemid 351682521)
201. Mannucci E, Monami M, Lamanna C, Gensini GF, Marchionni N. Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials. Diabetes Obes. Metab. 10(12), 1221-1238 (2008).
202. Dormandy JA, Charbonnel B, Eckland DJA et al. Secondary prevention of macrovascular events in patients with Type 2 diabetes in the Proactive Study (Prospective Pioglitazone Clinical Trial In Macrovascular Events): a randomised controlled trial. Lancet 366, 1279-1289 (2005). (Pubitemid 41416583)
203. Nesto RW, Bell D, Bonow RO et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. 7 October 2003. Circulation 108, 2941-2948 (2003). (Pubitemid 37517824)
204. Karalliedde J, Buckingham RE. Thiazolidinediones and their fluid-related adverse effects: facts, fiction and putative management strategies. Drug Saf. 30(9), 741-753 (2007). (Pubitemid 47347350)